Skip to main content

Advertisement

Table 1 Age and gender distribution of selected patients

From: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

   anti-CTLA-4 anti-PD-1
   responders non-responders responders non-responders
Age < 30 0 1 0 0
30–39 0 1 2 0
40–49 1 4 2 2
50–59 3 0 6 6
60–69 4 5 4 6
> 70 2 3 7 5
Ave. age (years) 62.3 56.4 61.3 61.4
STDEV (years) 10.9 17.7 15.3 11.6
p value (U test) 0.35 0.81
Gender Female 4 4 8 7
Male 6 10 13 12
Clinical response CR 0   2  
PR 2   12 (3 borderline CR)  
SD 8   7  
PD   14   19
  1. Age and gender distribution of patients in the anti-CTLA-4 and anti-PD-1 cohorts in relation to clinical response are shown. More details regarding patient sample selection can be found in the Materials and Methods section. p values shown are from U test between responders and non-responders. p < 0.05 was considered statistically significant